title: Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites.
abstract: The recombinant retrovirus, MoFe2-MuLV (MoFe2), was constructed by replacing the U3 region of Moloney murine leukemia virus (M-MuLV) with homologous sequences from the FeLV-945 LTR. NIH/Swiss mice neonatally inoculated with MoFe2 developed T-cell lymphomas of immature thymocyte surface phenotype. MoFe2 integrated infrequently (0 to 9%) near common insertion sites (CISs) previously identified for either parent virus. Using three different strategies, CISs in MoFe2-induced tumors were identified at six loci, none of which had been previously reported as CISs in tumors induced by either parent virus in wild-type animals. Two of the newly identified CISs had not previously been implicated in lymphoma in any retrovirus model. One of these, designated 3-19, encodes the p101 regulatory subunit of phosphoinositide-3-kinase-gamma. The other, designated Rw1, is predicted to encode a protein that functions in the immune response to virus infection. Thus, substitution of FeLV-945 U3 sequences into the M-MuLV long terminal repeat (LTR) did not alter the target tissue for M-MuLV transformation but significantly altered the pattern of CIS utilization in the induction of T-cell lymphoma. These observations support a growing body of evidence that the distinctive sequence and/or structure of the retroviral LTR determines its pattern of insertional activation. The findings also demonstrate the oligoclonal nature of retrovirus-induced lymphomas by demonstrating proviral insertions at CISs in subdominant populations in the tumor mass. Finally, the findings demonstrate the utility of novel recombinant retroviruses such as MoFe2 to contribute new genes potentially relevant to the induction of lymphoid malignancy.
authors.affiliation: Department of Microbiology and Immunology and Tulane Cancer Center, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA.
authors.forename: Chassidy
authors.initials: C
authors.lastname: Johnson
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Lobelle-Rich
authors.forename: Adriane
authors.initials: A
authors.lastname: Puetter
authors.forename: Laura S
authors.initials: LS
authors.lastname: Levy
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D002415:Cats; D004279:DNA, Viral / Q000235:genetics; D005256:Leukemia Virus, Feline / Q000235:genetics*; D007942:Leukemia, Experimental / Q000473:pathology / Q000821:virology; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000821:virology*; D051379:Mice; D008979:Moloney murine leukemia virus / Q000235:genetics* / Q000472:pathogenicity*; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics; D011533:Proviruses / Q000235:genetics; D011995:Recombination, Genetic; D012192:Retroviridae Infections / Q000473:pathology / Q000821:virology; D020079:Terminal Repeat Sequences / Q000235:genetics*; D014412:Tumor Virus Infections / Q000473:pathology / Q000821:virology; D016662:Virus Integration
chemical_list: D004279:DNA, Viral; D011518:Proto-Oncogene Proteins